This slide show highlights some of the top breast cancer news of 2016, including a study looking at optimal margins in DCIS, a trial on biosimilars, a new FDA approval, and more.
Pembrolizumab Maintenance Yields Enduring Responses in HER2– Breast Cancer
Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.
Managing CDK4/6 Inhibitor, ADC Toxicity in Metastatic Breast Cancer
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence
DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.
HER2CLIMB-02 Trial Shows ‘Interesting Data’ in HER2+ Breast Cancer
Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.
70 Navigating Lymphedema: The Impact of Indocyanine Green Lymphography (ICG_L) on Personalized Therapy Outcomes in Patients With Breast Cancer (BC)
Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.